|Awarded On||December 05, 2012|
|Title||Single-Cell Biomarkers of Clinical-Grade T Cells and NK Cells to Optimize Tumor Immunotherapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||University of Houston|
|Principal Investigator/Program Director||Navin Varadarajan|
|Cancer Sites||All Sites, Leukemia|
Adoptive cell therapy is a cutting-edge treatment option for diverse kinds of cancers. In this grant application we will employ a single-cell methodology to characterize the heterogeneity of cells used for adoptive cell therapy to better define the potency of cell based therapies. The successful implementation of the aims of the grant will facilitate more rapid translation of ACT based therapies and will ensure that Texans are the first to benefit from the next generation of clinical trials based on ACT.